Delving into the Latest Updates on Ascendis Pharma Growth Disorders A/S with Synapse

COACH: A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children with Achondroplasia - ASND0042

开始日期2024-07-26

申办/合作机构

Ascendis Pharma Growth Disorders A/S

NCT06433557 / Recruiting临床2期

A Phase 2, Open-Label, Single-Arm, 156-week Trial to Investigate the Efficacy, Safety and Tolerability of Combined Once Weekly Navepegritide and Lonapegsomatropin in Children With Achondroplasia

This proof-of-concept trial is being conducted to evaluate the efficacy, safety and tolerability of combination treatment with navepegritide and lonapegsomatropin administered as separate subcutaneous (SC) injections once weekly in children with achondroplasia (ACH) aged 2 to 11 years.

开始日期2024-07-26

申办/合作机构

Ascendis Pharma Growth Disorders A/S

CTIS2022-502202-33-00 / Recruiting

AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia - ASND0039

开始日期2023-07-06

申办/合作机构

Ascendis Pharma Growth Disorders A/S

100 项与 Ascendis Pharma Growth Disorders A/S 相关的临床结果

登录后查看更多信息

0 项与 Ascendis Pharma Growth Disorders A/S 相关的专利（医药）

登录后查看更多信息

100 项与 Ascendis Pharma Growth Disorders A/S 相关的药物交易

登录后查看更多信息

100 项与 Ascendis Pharma Growth Disorders A/S 相关的转化医学

登录后查看更多信息